In 2026, the only FDA-approved tesamorelin is Theratechnologies' Egrifta line, now centered on Egrifta WR (approved March 2025). It is a specialty brand drug, and insurers generally tie coverage to its one approved use: reducing excess abdominal fat in adults with HIV-associated lipodystrophy. Outside that indication you're usually paying cash for an off-label prescription. "Compounded tesamorelin" looks like the cheap way around this, but FDA lists tesamorelin among the products deemed biologics in 2020, and the agency says biologics aren't eligible for the compounding exemptions.
What you'd actually be buying
Tesamorelin is a synthetic analogue of growth hormone releasing hormone (GHRH). Our tesamorelin visceral fat breakdown covers the trial data. The short version: it reduced CT-measured visceral fat in adults with HIV-associated lipodystrophy, which is the population it's approved for.
The brand history matters for cost:
| Product | Approved | Notes |
|---|---|---|
| Egrifta | November 10, 2010 | Original formulation |
| Egrifta SV | November 2018 | Required reconstitution before each daily injection |
| Egrifta WR | March 25, 2025 | Reconstituted once weekly for daily injection; replacing SV |
Every version carries the same indication: reducing excess abdominal fat in HIV-infected adults with lipodystrophy. Dosing for prescription tesamorelin is set by the prescribing clinician under the label. We don't reproduce dosing instructions. See our medical disclaimer.
Why we're not printing a price
We looked for a current, primary-source price for Egrifta WR and couldn't confirm one. The figures that circulate online either have no date or no source. Rather than repeat a number we can't stand behind, here's what determines what you'd pay, and where to check:
- The pharmacy's cash price for the brand product, which you can compare using a price-comparison tool or by calling specialty pharmacies.
- Your insurance coverage, which mostly depends on whether you meet the approved indication.
- Manufacturer support programs, which brand makers often run for eligible patients. Ask the prescriber's office or the manufacturer directly.
- Visit and lab costs, which telehealth programs may bill separately from the drug.
Insurance: the indication decides
Plans typically require prior authorization for tesamorelin. Coverage criteria commonly include a documented HIV diagnosis, lipodystrophy with excess visceral fat (sometimes confirmed by imaging) and baseline waist measurements, and some plans require documented diet and lifestyle attempts first. Prior authorization can take weeks and may need an appeal if it's denied.
If you're a lifter without HIV who wants tesamorelin for belly fat, that's off-label use. A clinician may legally prescribe it, but expect your insurer to decline, which puts you on the brand cash price.
The compounding question
This is where most of the confusion and most of the "cheap tesamorelin" marketing sits.
On March 23, 2020, a set of protein products that had been approved as drugs were deemed biologics. FDA's list of those products includes "tesamorelin acetate, Egrifta and Egrifta SV."
FDA's notice to compounders is direct: transitioning biological products "will not be eligible for the exemptions for compounded drugs," and biological products licensed under the Public Health Service Act aren't eligible either. In practice, that means:
- A 503A pharmacy can't rely on the usual compounding exemptions to make tesamorelin from bulk powder.
- A 503B outsourcing facility can't either. Its CGMP status doesn't change biologic rules.
- A product sold as "compounded tesamorelin" is, by FDA's own documents, outside the compounding framework. If a clinic offers it, ask for the legal basis in writing.
Our 503A vs 503B explainer covers how these pharmacy categories work. Research-grade tesamorelin sold by peptide vendors is a separate channel: it isn't sold for human use and has no approved human dose.
Ask three questions: Which pharmacy makes it? Is it 503A or 503B? What legal basis lets that pharmacy compound a product FDA treats as a biologic? If the answers are vague, the low price is the least important thing you're being sold.
Off-label prescribing, in plain terms
Off-label means a clinician prescribes an approved drug for a use, population or purpose that isn't on its label. It's legal and common in medicine. What changes is the support around it. The label's trial data describe adults with HIV-associated lipodystrophy on antiretroviral therapy, not a 40-year-old lifter with ordinary central fat, so the benefit for you is an extrapolation. Insurers rarely pay for it. And the prescriber takes on the job of explaining why the expected benefit justifies the cost and the monitoring. A good prescriber will say all of that out loud. Our tesamorelin approval explainer covers what the label does and doesn't support.
What "research-grade" tesamorelin is not
Peptide vendors also list tesamorelin. Those products are sold for laboratory research, not for human use, and they come with no approved human dose and none of a dispensed prescription's protections: no prescriber, no pharmacist, no patient-specific label. They aren't a cheaper version of Egrifta. They're a different category entirely. If you're comparing GH-axis compounds in the research literature, our CJC-1295 vs tesamorelin comparison lays out the evidence gap between them.
Cost vs alternatives
Men usually come to tesamorelin from one of two directions: they want visceral fat down, or they want a prescription GH-axis peptide. For both goals it helps to compare the whole picture, not just the sticker price.
| Option | Status | Cost drivers | Evidence for the goal |
|---|---|---|---|
| Egrifta WR | FDA-approved (HIV lipodystrophy) | Brand specialty price; insurance only if indicated | Strong for visceral fat in its approved population |
| Compounded sermorelin | Compounded, not FDA-approved | Monthly cash subscriptions are typical | Limited for body composition in healthy men |
| GLP-1 medications | FDA-approved brands for weight management | Brand or self-pay channels; coverage varies | Large weight-loss trials, including fat loss |
| Training, diet, sleep | No prescription | Your time | The base layer for everyone |
For sermorelin specifically, our sermorelin cost guide covers what drives the price, and sermorelin vs tesamorelin compares the two molecules. The tesamorelin profile has the research summary.
Questions to ask a prescriber about tesamorelin
- Do I meet the approved indication, and if not, why do you think off-label use is justified for me?
- Will you request prior authorization, and what documentation will that need?
- Is the prescription for Egrifta WR, and which pharmacy will dispense it?
- What labs will you monitor, including IGF-1 and glucose?
- If cost rules it out, what would you suggest instead, and what's the evidence?
Tested athletes
Tesamorelin is named on the World Anti-Doping Agency's 2026 Prohibited List as a GHRH analogue under S2, prohibited at all times. Sermorelin and CJC-1295 are named in the same category.
A prescription pathway we link to
If tesamorelin isn't realistic for you, the GH-axis peptide most telehealth services offer is sermorelin. This is the service we link to; a clinician decides whether it's appropriate:
Joint pain, swelling, numbness or tingling in the hands, or signs of high blood sugar such as unusual thirst and frequent urination while on any GH-axis therapy should be reported to your prescriber promptly.
Sources
- FDA, List of approved NDAs for biological products deemed to be BLAs on March 23, 2020 (includes tesamorelin acetate, Egrifta and Egrifta SV).
- FDA, Notice to compounders: changes that affect compounding on March 23, 2020.
- Drugs.com, Egrifta WR FDA approval history (approval March 25, 2025; indication; formulation).
- Medfinder, Why is tesamorelin hard to find in 2026 (SV-to-WR transition, typical prior-authorization criteria).
- World Anti-Doping Agency, 2026 Prohibited List.
Frequently Asked
We could not confirm a current primary-source price for Egrifta WR, so we do not print one. Your cost depends on the pharmacy's cash price, whether your insurer covers it (usually only for the approved HIV lipodystrophy indication), any manufacturer support program, and separate visit and lab fees.
Insurers typically require prior authorization and tie coverage to the approved indication: excess abdominal fat in adults with HIV-associated lipodystrophy. Off-label use for general belly fat is usually not covered.
FDA lists tesamorelin among the products deemed biologics on March 23, 2020, and its notice to compounders says biological products are not eligible for the exemptions for compounded drugs. Ask any clinic offering compounded tesamorelin for the pharmacy name and the legal basis in writing.
Both are FDA-approved tesamorelin for the same indication. Egrifta SV required reconstitution before each daily injection, while Egrifta WR, approved in March 2025, is reconstituted once a week for daily injection. WR is replacing SV.
Yes. The 2026 WADA Prohibited List names tesamorelin as a growth hormone releasing hormone analogue under S2, prohibited at all times.